The body composition substudy The Lancet Diabetes and Endocrinology published a substudy specifically examining body composition changes using DXA scanning, the gold standard for measuring fat versus lean mass
Based on typical Phase 3 timelines, earliest realistic availability is 20292030 approximately 2 years after retatrutide's projected 2028 launch
More serious side effects including signs of kidney problems (such as change in the amount of urine), vision changes (such as decreased/blurred vision), signs of pancreatitis or gallbladder disease (such as nausea/vomiting that doesn`t stop, severe stomach/abdominal pain) should be reported to your doctor immediately
Your provider may recommend a washout or overlap plan if you are switching
Overlapping symptoms dont always rule out tirzepatide, but treatment decisions should be made with a medical doctor
It reduces appetite, limits overeating, and supports smaller portions and fewer cravings